{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:45:13Z","timestamp":1791477913989,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Endometrial cancer (EC) is one of the most common gynaecologic malignancies. Tumor infiltrating regulatory T-cells (Treg) have been reported to have a prognostic impact in many malignancies. Immunotherapeutic strategies are gaining interest for advanced and recurrent EC cases, where treatment options are rare. Our study was aimed at determining the value of Treg in EC progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>EC specimens from 275 patients and 28 controls were screened immunohistochemically for the presence of Treg represented by FoxP3. Correlations with clinicopathological and survival parameters were performed. Functional assays were performed using EC cell lines Ishikawa\u2009+\u2009and RL95-2 after co-culturing with isolated CD4\u2009+\u2009CD25\u2009+\u2009CD127dim Treg. To assess the influence of EC on the composition of peripheral blood mononuclear cells (PBMC), flow cytometric analyses were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that an increased infiltration of Treg was associated with high grades and a reduced overall survival. Treg were almost absent in endometrium tissues from healthy control patients. Co-culture of tumor cells with CD4\u2009+\u2009CD25\u2009+\u2009CD127dim Treg led to functional changes: enhanced invasion, migration and viability indicated that increased levels of Treg in the tumor microenvironment may promote tumor growth. Furthermore, we found that the presence of EC cells led to phenotypic changes in PBMC, showing significantly increased levels of CD25 and FoxP3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results indicate that the presence of Treg in the EC tumor environment is associated with a poorer outcome. A remarkable impact of Treg on tumor cell behaviour and vice versa of tumor cells on PBMC subpopulations support this notion mechanistically. Our findings provide a basis for focusing on Treg as potential future therapeutic targets in EC.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s13402-022-00708-2","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T15:11:57Z","timestamp":1663081917000},"page":"1171-1185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cells"],"prefix":"10.1007","volume":"45","author":[{"given":"Thomas","family":"Kolben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Mannewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Perleberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Anz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Schmoeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Czogalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Jeschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Trillsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"708_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","author":"F Bray","year":"2018","unstructured":"F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018). https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin."},{"key":"708_CR2","unstructured":"American Cancer Society in Cancer Facts and Figures 2014. Atlanta, American Cancer Society. http:\/\/www.cancer.org\/ Accessed 27 October 2020"},{"key":"708_CR3","first-page":"468","volume":"93","author":"MM Braun","year":"2016","unstructured":"M.M. Braun, E.A. Overbeek-Wager, R.J. Grumbo, Diagnosis and management of endometrial cancer. Am Fam Physician. 93, 468\u2013474 (2016)","journal-title":"Am Fam Physician."},{"key":"708_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(83)90111-7","author":"JV Bokhman","year":"1983","unstructured":"J.V. Bokhman, Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. (1983). https:\/\/doi.org\/10.1016\/0090-8258(83)90111-7","journal-title":"Gynecol Oncol."},{"key":"708_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000822","author":"F Legge","year":"2020","unstructured":"F. Legge, S. Restaino, L. Leone, V. Carone, C. Ronsini, G.L.M. Di Fiore et al., Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment. Int J Gynecol Cancer. (2020). https:\/\/doi.org\/10.1136\/ijgc-2019-000822","journal-title":"Int J Gynecol Cancer."},{"key":"708_CR6","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102817","author":"P Chen","year":"2020","unstructured":"P. Chen, Y. Yang, Y. Zhang, S. Jiang, X. Li, J. Wan, Identification of prognostic immune-related genes in the tumor microenvironment of endometrial cancer. Aging (Albany NY). (2020). https:\/\/doi.org\/10.18632\/aging.102817","journal-title":"Aging (Albany NY)."},{"key":"708_CR7","doi-asserted-by":"publisher","unstructured":"H. Ding, G.L. Fan, Y.X. Yi, W. Zhang, X.X Xiong, O.K. Mahgoub, Prognostic Implications of Immune-Related Genes' (IRGs) Signature Models in Cervical Cancer and Endometrial Cancer. Front Genet. (2020).\u00a0https:\/\/doi.org\/10.3389\/fgene.2020.00725","DOI":"10.3389\/fgene.2020.00725"},{"key":"708_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5952","author":"PA Ott","year":"2017","unstructured":"P.A. Ott, Y.J. Bang, D. Berton-Rigaud, E. Elez, M.J. Pishvaian, H.S. Rugo et al., Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. (2017). https:\/\/doi.org\/10.1200\/JCO.2017.72.5952","journal-title":"J Clin Oncol."},{"key":"708_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2655","author":"JB Pakish","year":"2017","unstructured":"J.B. Pakish, Q. Zhang, Z. Chen, H. Liang, G.B. Chisholm, Y. Yuan et al., Immune microenvironment in microsatellite-instable endometrial cancers: Hereditary or sporadic origin matters. Clin Cancer Res. (2017). https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2655","journal-title":"Clin Cancer Res."},{"key":"708_CR10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962","author":"DC Hinshaw","year":"2019","unstructured":"D.C. Hinshaw, L.A. Shevde, The tumor microenvironment innately modulates cancer progression. Cancer Res. (2019). https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3962","journal-title":"Cancer Res."},{"key":"708_CR11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.2.287","author":"AM Thornton","year":"1998","unstructured":"A.M. Thornton, E.M. Shevach, CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. (1998). https:\/\/doi.org\/10.1084\/jem.188.2.287","journal-title":"J Exp Med."},{"key":"708_CR12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, M. Toda, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 155, 1151\u201364 (1995)","journal-title":"J Immunol."},{"key":"708_CR13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.5.2756","author":"UK Liyanage","year":"2002","unstructured":"U.K. Liyanage, T.T. Moore, H.-G. Joo, Y. Tanaka, V. Herrmann, G. Doherty et al., Prevalence of regulatory t cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. (2002). https:\/\/doi.org\/10.4049\/jimmunol.169.5.2756","journal-title":"J. Immunol."},{"key":"708_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3232","author":"LA Ormandy","year":"2005","unstructured":"L.A. Ormandy, T. Hillemann, H. Wedemeyer, M.P. Manns, T.F. Greten, F. Korangy, Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. (2005). https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3232","journal-title":"Cancer Res."},{"key":"708_CR15","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","volume":"163","author":"J Shimizu","year":"1999","unstructured":"J. Shimizu, S. Yamazaki, S. Sakaguchi, Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 163, 5211\u20135218 (1999)","journal-title":"J Immunol."},{"key":"708_CR16","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2021.32.e30","author":"Y Cheng","year":"2021","unstructured":"Y. Cheng, X. Li, Y. Dai, Y. Dong, X. Yang, J. Wang, Identification of an immune-related risk signature and nomogram predicting the overall survival in patients with endometrial cancer. J Gynecol Oncol. (2021). https:\/\/doi.org\/10.3802\/jgo.2021.32.e30","journal-title":"J Gynecol Oncol."},{"key":"708_CR17","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2013.107","author":"M Takenaka","year":"2013","unstructured":"M. Takenaka, N. Seki, U. Toh, S. Hattori, A. Kawahara, T. Yamaguchi et al., FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol. (2013). https:\/\/doi.org\/10.3892\/mco.2013.107","journal-title":"Mol Clin Oncol."},{"key":"708_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0442-x","author":"LM Charbonnier","year":"2019","unstructured":"L.M. Charbonnier, Y. Cui, E. Stephen-Victor, H. Harb, D. Lopez, J.J. Bleesing et al., Functional reprogramming of regulatory T cells in the absence of Foxp3. Nat Immunol. (2019). https:\/\/doi.org\/10.1038\/s41590-019-0442-x","journal-title":"Nat Immunol."},{"key":"708_CR19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.1444","author":"M Viguier","year":"2004","unstructured":"M. Viguier, F. Lema\u00eetre, O. Verola, M.S. Cho, G. Gorochov, L. Dubertret et al., Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. (2004). https:\/\/doi.org\/10.4049\/jimmunol.173.2.1444","journal-title":"J Immunol."},{"key":"708_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526189","author":"G Roncador","year":"2005","unstructured":"G. Roncador, P.J. Brown, L. Maestre, S. Hue, J.L. Mart\u00ednez-Torrecuadrada, K.L. Ling et al., Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol. (2005). https:\/\/doi.org\/10.1002\/eji.200526189","journal-title":"Eur J Immunol."},{"key":"708_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25016","author":"D Wolf","year":"2015","unstructured":"D. Wolf, S. Sopper, A. Pircher, G. Gastl, A.M. Wolf, Treg(s) in cancer: Friends or foe? J Cell Physiol. (2015). https:\/\/doi.org\/10.1002\/jcp.25016","journal-title":"J Cell Physiol."},{"key":"708_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4086","author":"T Saito","year":"2016","unstructured":"T. Saito, H. Nishikawa, H. Wada, Y. Nagano, D. Sugiyama, K. Atarashi et al., Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. (2016). https:\/\/doi.org\/10.1038\/nm.4086","journal-title":"Nat Med."},{"key":"708_CR23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1316796110","author":"D Sugiyama","year":"2013","unstructured":"D. Sugiyama, H. Nishikawa, Y. Maeda, M. Nishioka, A. Tanemura, I. Katayama et al., Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A. (2013). https:\/\/doi.org\/10.1073\/pnas.1316796110","journal-title":"Proc Natl Acad Sci U S A."},{"key":"708_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1316796110","author":"T Ishida","year":"2006","unstructured":"T. Ishida, R. Ueda, CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. (2006). https:\/\/doi.org\/10.1073\/pnas.1316796110","journal-title":"Cancer Sci."},{"key":"708_CR25","first-page":"262","volume":"36","author":"NP Iurchenko","year":"2014","unstructured":"N.P. Iurchenko, N.M. Glushchenko, L.G. Buchynska, Comprehensive analysis of intratumoral lymphocytes and FOXP3 expression in tumor cells of endometrial cancer. Exp Oncol. 36, 262\u2013266 (2014)","journal-title":"Exp Oncol."},{"key":"708_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/path.4381","author":"S Douglass","year":"2014","unstructured":"S. Douglass, A.P. Meeson, D. Overbeck-Zubrzycka, J.G. Brain, M.R. Bennett, C.A. Lamb et al., Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12. J Pathol. (2014). https:\/\/doi.org\/10.1002\/path.4381","journal-title":"J Pathol."},{"key":"708_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31822c271f","author":"W Yamagami","year":"2011","unstructured":"W. Yamagami, N. Susumu, H. Tanaka, A. Hirasawa, K. Banno, N. Suzuki et al., Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer. (2011). https:\/\/doi.org\/10.1097\/IGC.0b013e31822c271f","journal-title":"Int J Gynecol Cancer."},{"key":"708_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1805764","author":"F Guo","year":"2020","unstructured":"F. Guo, Y. Dong, Q. Tan, J. Kong, B. Yu, Tissue infiltrating immune cells as prognostic biomarkers in endometrial cancer: a meta-analysis. Dis Markers. (2020). https:\/\/doi.org\/10.1155\/2020\/1805764","journal-title":"Dis Markers."},{"key":"708_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2008.12.008","author":"J Prat","year":"2009","unstructured":"J. Prat, FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. (2009). https:\/\/doi.org\/10.1016\/j.ijgo.2008.12.008","journal-title":"Int J Gynaecol Obstet."},{"key":"708_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000518","author":"RA Soslow","year":"2019","unstructured":"R.A. Soslow, C. Tornos, K.J. Park, A. Malpica, X. Matias-Guiu, E. Oliva et al., Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. (2019). https:\/\/doi.org\/10.1097\/PGP.0000000000000518","journal-title":"Int J Gynecol Pathol."},{"key":"708_CR31","unstructured":"American Cancer Society in Endometrial cancer. Atlanta, American Cancer Society. https:\/\/www.cancer.org. Accessed 24 February 2021"},{"key":"708_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093","author":"TJ Curiel","year":"2004","unstructured":"T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. (2004). https:\/\/doi.org\/10.1038\/nm1093","journal-title":"Nat Med."},{"key":"708_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0092-8","author":"K Kono","year":"2006","unstructured":"K. Kono, H. Kawaida, A. Takahashi, H. Sugai, K. Mimura, N. Miyagawa et al., CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. (2006). https:\/\/doi.org\/10.1007\/s00262-005-0092-8","journal-title":"Cancer Immunol Immunother."},{"key":"708_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602407","author":"C Schaefer","year":"2005","unstructured":"C. Schaefer, G.G. Kim, A. Albers, K. Hoermann, E.N. Myers, T.L. Whiteside, Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. (2005). https:\/\/doi.org\/10.1038\/sj.bjc.6602407","journal-title":"Br J Cancer."},{"key":"708_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12736","author":"X Ke","year":"2019","unstructured":"X. Ke, L. Shen, Targeting cytokines secreted by CD4(+) CD25(high) CD127(low) regulatory T cells inhibits ovarian cancer progression. Scand J Immunol. (2019). https:\/\/doi.org\/10.1111\/sji.12736","journal-title":"Scand J Immunol."},{"key":"708_CR36","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.5136","author":"Q Zhu","year":"2016","unstructured":"Q. Zhu, X. Wu, Y. Wu, X. Wang, Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Oncol Rep. (2016). https:\/\/doi.org\/10.3892\/or.2016.5136","journal-title":"Oncol Rep."},{"key":"708_CR37","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.8606","author":"J Peng","year":"2018","unstructured":"J. Peng, Z. Yu, L. Xue, J. Wang, J. Li, D. Liu et al., The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells. Mol Med Rep. (2018). https:\/\/doi.org\/10.3892\/mmr.2018.8606","journal-title":"Mol Med Rep."},{"key":"708_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2018.12.004","author":"H Jia","year":"2019","unstructured":"H. Jia, H. Qi, Z. Gong, S. Yang, J. Ren, Y. Liu et al., The expression of FOXP3 and its role in human cancers. Biochim Biophys Acta Rev Cancer. (2019). https:\/\/doi.org\/10.1016\/j.bbcan.2018.12.004","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"708_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016345","author":"Z Xi","year":"2019","unstructured":"Z. Xi, L. Jing, K. Le-Ni, L. Zhu, D. Ze-Wen, Y. Hui et al., Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study. Medicine (Baltimore). (2019). https:\/\/doi.org\/10.1097\/MD.0000000000016345","journal-title":"Medicine (Baltimore)"},{"key":"708_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0172-x","author":"S Asaka","year":"2019","unstructured":"S. Asaka, T.T. Yen, T.L. Wang, I.M. Shih, S. Gaillard, T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Mod Pathol. (2019). https:\/\/doi.org\/10.1038\/s41379-018-0172-x","journal-title":"Mod Pathol."},{"key":"708_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.03.022","author":"RA de Jong","year":"2009","unstructured":"R.A. de Jong, N. Leffers, H.M. Boezen, K.A. ten Hoor, A.G.J. van der Zee, H. Hollema et al., Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol. Oncol. (2009). https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.022","journal-title":"Gynecol. Oncol."},{"key":"708_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.08.028","author":"K Kubler","year":"2014","unstructured":"K. Kubler, T.H. Ayub, S.K. Weber, O. Zivanovic, A. Abramian, M.D. Keyver-Paik et al., Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol Oncol. (2014). https:\/\/doi.org\/10.1016\/j.ygyno.2014.08.028","journal-title":"Gynecol Oncol."},{"key":"708_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.04.021","author":"A Giatromanolaki","year":"2008","unstructured":"A. Giatromanolaki, G.J. Bates, M.I. Koukourakis, E. Sivridis, K.C. Gatter, A.L. Harris et al., The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol. Oncol. (2008). https:\/\/doi.org\/10.1016\/j.ygyno.2008.04.021","journal-title":"Gynecol. Oncol."},{"key":"708_CR44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4316","author":"PB Olkhanud","year":"2011","unstructured":"P.B. Olkhanud, B. Damdinsuren, M. Bodogai, R.E. Gress, R. Sen, K. Wejksza et al., Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res. (2011). https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-4316","journal-title":"Cancer Res."},{"key":"708_CR45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4619","author":"PB Olkhanud","year":"2009","unstructured":"P.B. Olkhanud, D. Baatar, M. Bodogai, F. Hakim, R. Gress, R.L. Anderson et al., Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. (2009). https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4619","journal-title":"Cancer Res."},{"key":"708_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700540","author":"M Cao","year":"2007","unstructured":"M. Cao, R. Cabrera, Y. Xu, R. Firpi, H. Zhu, C. Liu et al., Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab Invest. (2007). https:\/\/doi.org\/10.1038\/labinvest.3700540","journal-title":"Lab Invest."},{"key":"708_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01951.x","author":"L Du","year":"2011","unstructured":"L. Du, X. Xiao, C. Wang, X. Zhang, N. Zheng, L. Wang et al., Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Cancer Sci. (2011). https:\/\/doi.org\/10.1111\/j.1349-7006.2011.01951.x","journal-title":"Cancer Sci."},{"key":"708_CR48","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i15.2019","author":"XL Yuan","year":"2011","unstructured":"X.L. Yuan, L. Chen, T.T. Zhang, Y.H. Ma, Y.L. Zhou, Y. Zhao et al., Gastric cancer cells induce human CD4+Foxp3+ regulatory T cells through the production of TGF-\u03b21. World J Gastroenterol. (2011). https:\/\/doi.org\/10.3748\/wjg.v17.i15.2019","journal-title":"World J Gastroenterol."},{"key":"708_CR49","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.2893","author":"J Liu","year":"2015","unstructured":"J. Liu, H. Zhang, L. Jia, H. Sun, Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditions. Mol Med Rep. (2015). https:\/\/doi.org\/10.3892\/mmr.2014.2893","journal-title":"Mol Med Rep."},{"key":"708_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.06.001","author":"GM Wiedemann","year":"2019","unstructured":"G.M. Wiedemann, N. Rohrle, M.C. Makeschin, J. Fesseler, S. Endres, D. Mayr et al., Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate. Pathology. (2019). https:\/\/doi.org\/10.1016\/j.pathol.2019.06.001","journal-title":"Pathology"},{"key":"708_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/srep18057","author":"NN Zhang","year":"2015","unstructured":"N.N. Zhang, J.N. Chen, L. Xiao, F. Tang, Z.G. Zhang, Y.W. Zhang et al., Accumulation mechanisms of CD4(+)CD25(+)FOXP3(+) regulatory T cells in EBV-associated gastric carcinoma. Sci Rep. (2015). https:\/\/doi.org\/10.1038\/srep18057","journal-title":"Sci Rep."},{"key":"708_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102310","author":"T Alissafi","year":"2019","unstructured":"T. Alissafi, A. Hatzioannou, A.I. Legaki, A. Varveri, P. Verginis, Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. J Autoimmun. (2019). https:\/\/doi.org\/10.1016\/j.jaut.2019.102310","journal-title":"J Autoimmun."},{"key":"708_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151","author":"A Tanaka","year":"2017","unstructured":"A. Tanaka, S. Sakaguchi, Regulatory T cells in cancer immunotherapy. Cell Res. (2017). https:\/\/doi.org\/10.1038\/cr.2016.151","journal-title":"Cell Res."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-022-00708-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-022-00708-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-022-00708-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T23:14:49Z","timestamp":1676762089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-022-00708-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s13402-022-00708-2","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"17 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study was approved by the ethics committee of the Ludwig-Maximilians-University Munich (reference number: 048\u201308; 2008). Patient data were anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable as all data are anonymized.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable as all data are anonymized.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"T. Kolben has a relative employed at Roche and holds stock of Roche. F. Trillsch declares Research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Medac, PharmaMar, Roche, Tesaro. S. Mahner has received Research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Medac, MSD, Novartis, Olympus, PharmaMar, Roche, Sensor Kinesis, Teva, Tesaro. All other authors declare that they have no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}